Is abemaciclib a targeted therapy or an endocrine therapy?

Abemaciclib is commonly available in tablet form and is typically a targeted therapy drug. A detailed analysis is as follows:

Abemaciclib specifically inhibits the activity of cyclin-dependent kinases 4 and 6, blocking the signal transduction involved in cancer cell proliferation, thereby suppressing tumor growth. Its mechanism of action targets specific molecular sites within cancer cells, consistent with the characteristics of targeted drugs that precisely act on affected areas.

Abemaciclib does not exert anti-tumor effects by regulating hormone levels in the body. Its mechanism differs from that of endocrine drugs, which treat diseases by affecting hormone secretion or function, and therefore, abemaciclib does not belong to the category of endocrine drugs.

Abemaciclib should be taken strictly according to the dosage and treatment duration prescribed by a physician. Close attention should be paid to bodily reactions during treatment. Maintaining a healthy lifestyle, improving dietary habits, engaging in appropriate physical exercise, enhancing physical fitness, and reducing the risk of illness are also important.